Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
ANABSAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, filed a partial motion to dismiss Tesaro’s anticipatory breach of contract claim in Delaware Chancery Court related to pending litigation between Anaptys, GSK, and TESARO, Inc. (“Tesaro”) regarding their Collaboration and Exclusive License Agreement (“Collaboration Agreement”), which entitles Anaptys to receive royalties upon sales of Jemperli.
Anaptys Announces Participation in September Investor Conferences
ANABSAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:
Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update
ANABSAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the second quarter ended June 30, 2025, and provided a business update.
Crude Oil Falls Over 1%; ISM Services PMI Tumbles In May
ANABThis Snowflake Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
ANABHC Wainwright & Co. Upgrades AnaptysBio to Buy, Raises Price Target to $38
ANABAnaptys Reports Rosnilimab Data Updated Through Six Months In Phase 2b Trial In RA
ANABBeyond The Numbers: 5 Analysts Discuss AnaptysBio Stock
ANABHeico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday
ANABGuggenheim Maintains Buy on AnaptysBio, Raises Price Target to $90
ANABAnaptysBio To Reveal Updated Data From Phase 2b Trial of Rosnilimab, A PD-1 Depleter And Agonist, For Rheumatoid Arthritis On June 3, 2025
ANABForecasting The Future: 6 Analyst Projections For AnaptysBio
ANABGuggenheim Maintains Buy on AnaptysBio, Raises Price Target to $54
ANABAnaptysBio Q1 EPS $(1.28) Misses $(1.25) Estimate, Sales $27.77M Beat $15.27M Estimate
ANABWedbush Reiterates Outperform on AnaptysBio, Maintains $40 Price Target
ANABCrude Oil Gains 1%; US Composite PMI Surges In March
ANABIntuitive Machines Posts Q4 Results, Joins Tesla, AnaptysBio, Coherent And Other Big Stocks Moving Higher On Monday
ANABAnaptys Announces $75M Share Buyback Program
ANABJP Morgan Maintains Overweight on AnaptysBio, Raises Price Target to $42
ANABWhere AnaptysBio Stands With Analysts
ANABHC Wainwright & Co. Reiterates Neutral on AnaptysBio, Maintains $22 Price Target
ANABAnaptysBio Q4 2024 GAAP EPS $(0.72) Beats $(1.62) Estimate, Sales $43.113 Miss $7.767M Estimate
ANABGilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday
ANABAnaptysBio's Rosnilimab Shows Results for Rheumatoid Arthritis, Hits Key Endpoints in Phase 2b Trial
ANABTrading Halt: Halted at 7:16:46 a.m. ET - Trading Halt: Halt News Pending
ANABWhy Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
ANABJP Morgan Maintains Overweight on AnaptysBio, Lowers Price Target to $36
ANABHC Wainwright & Co. Maintains Buy on AnaptysBio, Lowers Price Target to $52
ANABAnaptysBio Q3 EPS $(1.14) Beats $(1.65) Estimate, Sales $30.02M Beat $6.87M Estimate
ANABHC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $55 Price Target
ANABTruist Securities Downgrades AnaptysBio to Hold, Lowers Price Target to $28
ANABAnaptysBio Sells Royalty Interest In Cancer Drug For $45M
ANABAnaptysBio Announces Sale Of Zejula Royalties For Up To $45M
ANABPoint72 Asset Management In 13G Filing Reports 8.1% Passive Stake In AnaptysBio
ANABAnaptysBio Q1 EPS $(1.31) Down From $(0.66) YoY
ANABAnaptysBio Posts Topline Data From ANB032 Study In Healthy Volunteers
ANAB